TPTB continue to suppress Ivermectin:
“Yet, suddenly, without an explanation from Merck—who is a key manufacturer of the generic, readily available drug Ivermectin—MedPage Today reports that PRINCIPLE’s trial on the drug is paused, stating:
“The Ivermectin arm of the U.K.’s PRINCIPLE trial is “currently paused due to temporary supply issues.”
With over 5,000 people signed up for the study, participants were randomly assigned to receive a three-day course of Ivermectin treatment. The trial was set to offer meaningful and much-anticipated data. And despite the current demand for Ivermectin, a robust supply is typically available, making the supply issue challenging to understand. Without question, the market caused by off-label usage has been substantial as prescriptions in the U.S. went from a few thousand per week pre-pandemic to nearly 90,000 per week during the pandemic. Nonetheless, this drug is straightforward to produce, and there are multiple suppliers.”
https://uncoverdc.com/2021/12/16/supply-issues-pause-uk-ivermectin-trial-as-merck-lands-2-2b-us-govt-contract-for-new-drug/